Fresenius SE EBITDA Margin 2016-2024 | FSNUY
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Fresenius SE (FSNUY) over the last 10 years. The current EBITDA margin for Fresenius SE as of June 30, 2024 is .
| Fresenius SE EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-06-30 |
$13.94B |
$1.42B |
10.17% |
| 2024-03-31 |
$19.35B |
$2.16B |
11.16% |
| 2023-12-31 |
$24.13B |
$2.84B |
11.76% |
| 2023-09-30 |
$39.20B |
$4.42B |
11.27% |
| 2023-06-30 |
$43.73B |
$6.23B |
14.24% |
| 2023-03-31 |
$43.10B |
$6.44B |
14.95% |
| 2022-12-31 |
$43.03B |
$6.63B |
15.41% |
| 2022-09-30 |
$43.53B |
$7.15B |
16.42% |
| 2022-06-30 |
$43.99B |
$7.49B |
17.02% |
| 2022-03-31 |
$44.47B |
$7.90B |
17.77% |
| 2021-12-31 |
$44.39B |
$8.08B |
18.19% |
| 2021-09-30 |
$44.08B |
$8.03B |
18.21% |
| 2021-06-30 |
$43.51B |
$8.20B |
18.85% |
| 2021-03-31 |
$42.19B |
$8.14B |
19.29% |
| 2020-12-31 |
$41.44B |
$8.11B |
19.57% |
| 2020-09-30 |
$40.66B |
$8.15B |
20.05% |
| 2020-06-30 |
$40.06B |
$7.99B |
19.93% |
| 2020-03-31 |
$40.09B |
$7.95B |
19.84% |
| 2019-12-31 |
$39.66B |
$7.93B |
20.00% |
| 2019-09-30 |
$39.42B |
$7.61B |
19.31% |
| 2019-06-30 |
$39.12B |
$7.27B |
18.59% |
| 2019-03-31 |
$39.27B |
$8.10B |
20.64% |
| 2018-12-31 |
$39.60B |
$7.89B |
19.93% |
| 2018-09-30 |
$39.76B |
$7.72B |
19.41% |
| 2018-06-30 |
$39.98B |
$7.90B |
19.75% |
| 2018-03-31 |
$39.37B |
$6.85B |
17.40% |
| 2017-12-31 |
$38.30B |
$6.81B |
17.78% |
| 2017-09-30 |
$36.47B |
$6.83B |
18.71% |
| 2017-06-30 |
$34.84B |
$6.56B |
18.82% |
| 2017-03-31 |
$33.47B |
$6.38B |
19.07% |
| 2016-12-31 |
$32.18B |
$6.09B |
18.91% |
| 2016-09-30 |
$31.71B |
$12.34B |
38.92% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$20.921B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
